2025
One-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma.
Dholaria H, Tsetlina V, Simpson S, Gillies E, Eswaran N, Rodriguez-Galindo C, Schultz K, Chen K, Wu C, Krasin M, Roemer T, Christiansen H, Piao J, Laetsch T, Pashankar F, Kontny U, Gartrell R. One-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma. Clinical Cancer Research 2025, of1-of9. PMID: 40445588, DOI: 10.1158/1078-0432.ccr-24-3546.Peer-Reviewed Original ResearchGerman Society of Pediatric Oncology and HematologyChildren's Oncology GroupNasopharyngeal carcinomaClinical trialsAnti-PD-1 therapyRadiation doseDecreased radiation dosePediatric clinical trialsSevere side effectsConcomitant chemotherapyAdjuvant immunotherapyInduction chemotherapyOncology GroupRelated toxicityTreated patientsExcellent survivalSide effectsChemotherapyLate effectsLong-term effectsImmunotherapyCarcinomaClinical priorityDoseResponse-adaptive
2024
Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56‐positive acute leukemias
Hamdan H, Liu Y, Wang S, Bledsoe J, Chisholm K, Siddon A, Ohgami R, George T, Kurzer J, Hasserjian R, Arber D, Bagg A, Foucar K, Margolskee E, Laczko D, Chen W, Fuda F, Aggarwal N, Weinberg O. Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56‐positive acute leukemias. EJHaem 2024, 6: e1052. PMID: 39866946, PMCID: PMC11756974, DOI: 10.1002/jha2.1052.Peer-Reviewed Original ResearchAcute myeloid leukemiaAcute undifferentiated leukemiaExpression of CD56Children's Oncology GroupAcute leukemiaRAM immunophenotypeBlast percentageHLA-DRMyeloid leukemiaT-ALLBone marrowBright expressionFrequency of abnormal karyotypesWeak to absent expressionCharacteristics of acute myeloid leukemiaAcute myeloid leukemia groupAcute myeloid leukemia casesBCL6 co-repressorBM blast percentageWhite blood cell countAcute leukemia casesClinical differential diagnosisControl groupClinical outcome analysisNext-generation sequencing profilingEvaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group
Sargen M, Barnhill R, Elder D, Swetter S, Prieto V, Ko J, Bahrami A, Gerami P, Karunamurthy A, Pappo A, Schuchter L, LeBoit P, Yeh I, Kirkwood J, Jen M, Dunkel I, Durham M, Christison-Lagay E, Austin M, Aldrink J, Mehrhoff C, Hawryluk E, Chu E, Busam K, Sondak V, Messina J, Puig S, Colebatch A, Coughlin C, Berrebi K, Laetsch T, Mitchell S, Seynnaeve B. Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. Journal Of Clinical Oncology 2024, 43: 1157-1167. PMID: 39365959, PMCID: PMC11908957, DOI: 10.1200/jco.24.01154.Peer-Reviewed Original ResearchSentinel lymph node biopsyAtypical Spitz tumorsCutaneous melanomaSpitz tumorsRe-ExcisionSurgical managementMelanocytic tumorsSurgical management of cutaneous melanomaManagement of cutaneous melanomaNational Comprehensive Cancer Network guidelinesLymph node biopsyDefinitive surgical treatmentProgression to CMChildren's Oncology GroupDiagnosis of CMNode biopsyExcisional biopsyOncology GroupMalignant potentialSurgical treatmentNetwork guidelinesBiopsyClinicopathological evaluationCohort studyMelanocytic neoplasmsSurgical management of rare tumors (Part 1)
Stetson A, Saluja S, Cameron D, Mansfield S, Polites S, Honeyman J, Dahl J, Austin M, Aldrink J, Christison‐Lagay E. Surgical management of rare tumors (Part 1). Pediatric Blood & Cancer 2024, 72: e31287. PMID: 39185712, DOI: 10.1002/pbc.31287.Peer-Reviewed Original ResearchOncology GroupManagement of rare tumorsEuropean Cooperative Study GroupDifferentiated thyroid cancerRare tumor typeRare pediatric cancerChildren's Oncology GroupCooperative Study GroupCooperative group effortsChildren Aged 0Rare tumorAdult guidelinesSurgical managementThyroid cancerTumor typesRare cancersPediatric variantsTreatment strategiesStudy groupPediatric cancerCancer typesCancerTumorChildhood cancerAged 0
2023
Children's Oncology Group's 2023 blueprint for research: Surgery
Gow K, Lautz T, Malek M, Cost N, Newman E, Dasgupta R, Christison‐Lagay E, Tiao G, Davidoff A, Committee T. Children's Oncology Group's 2023 blueprint for research: Surgery. Pediatric Blood & Cancer 2023, 71: e30766. PMID: 37950538, PMCID: PMC10872730, DOI: 10.1002/pbc.30766.Peer-Reviewed Original ResearchCritical elements of pediatric neuroblastoma surgery
Shaffiey S, Le H, Christison-Lagay E, Fialkowski E, Aldrink J, Grant C, Honeyman J, Janek K, Madonna M, Rhee D, Nuchtern J, Newman E, LaQuaglia M, Davidoff A, Shamberger R, Malek M. Critical elements of pediatric neuroblastoma surgery. Seminars In Pediatric Surgery 2023, 32: 151338. PMID: 38042090, DOI: 10.1016/j.sempedsurg.2023.151338.Peer-Reviewed Original ResearchConceptsHigh-risk neuroblastomaOncology GroupChildren's Oncology GroupPediatric surgical oncologyLong-term survivalNeuroblastoma surgeryExtracranial malignanciesEffective surgeryPediatric oncologyChildhood cancerSurgical oncologyNeuroblastomaSurgeryInternational SocietyOncologyExpert opinionLiterature reviewPatientsMalignancyCancerIncidenceImportant roleOutcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
Weiss A, Chen Y, Scharschmidt T, Xue W, Gao Z, Black J, Choy E, Davis J, Fanburg-Smith J, Kao S, Kayton M, Kessel S, Lim R, Million L, Okuno S, Ostrenga A, Parisi M, Pryma D, Randall R, Rosen M, Shulkin B, Terezakis S, Venkatramani R, Zambrano E, Wang D, Hawkins D, Spunt S. Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. Journal Of Clinical Oncology 2023, 41: 4842-4848. PMID: 37523624, PMCID: PMC10852395, DOI: 10.1200/jco.23.00045.Peer-Reviewed Original ResearchConceptsNon-rhabdomyosarcoma soft tissue sarcomasSoft tissue sarcomasRegimen BPreoperative chemoradiationRegimen ATissue sarcomasPathological responseMedian survivor follow-upComplete pathologic response ratePathological response rateEvent-free survivalPhase II studyPrimary end pointChildren's Oncology GroupIntent-to-treat analysisSurvivor follow-upNon-rhabdomyosarcomasPreoperative radiotherapyPrimary resectionOverall survivalOncology GroupII studyClinical trial updateNRG OncologyEligible patientsRadiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group
Mailhot Vega R, Harker-Murray P, Forlenza C, Cole P, Kelly K, Milgrom S, Parikh R, Hodgson D, Castellino S, Kahn J, Roberts K, Constine L, Hoppe B. Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: 400-403. PMID: 37116589, PMCID: PMC10655744, DOI: 10.1016/j.ijrobp.2023.04.022.Peer-Reviewed Original ResearchConceptsOncology GroupYoung adult Hodgkin lymphomaAdult Hodgkin lymphomaChildren's Oncology GroupRadiation therapy useTherapy useHodgkin's lymphomaLymphomaRhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
Vasquez J, Luo L, Hiniker S, Rhee D, Dasgupta R, Chen S, Weigel B, Xue W, Venkatramani R, Arndt C. Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatric Blood & Cancer 2023, 70: e30293. PMID: 36916768, PMCID: PMC10424503, DOI: 10.1002/pbc.30293.Peer-Reviewed Original ResearchConceptsEvent-free survivalMetastatic diseaseYears of ageOverall survivalOncology GroupLung metastasesExact testSoft Tissue Sarcoma CommitteeSuperior event-free survivalBetter survival outcomesKaplan-Meier methodChildren's Oncology GroupRisk stratification algorithmLog-rank testOutcome of childrenFisher's exact testN0 diseaseAggressive treatmentMetastatic rhabdomyosarcomaExtrapulmonary sitesMetastatic sitesExtremity tumorsSurvival outcomesEmbryonal histologyCOG protocolsLoss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group
Puthenpura V, Ji L, Xu X, Roth M, Freyer D, Frazier A, Marks A, Pashankar F. Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group. Cancer 2023, 129: 1547-1556. PMID: 36813754, PMCID: PMC10357561, DOI: 10.1002/cncr.34701.Peer-Reviewed Original ResearchConceptsClinical trial participantsNon-Hispanic blacksTrial participantsHazard ratioOncology GroupClinical trialsMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelChildren's Oncology Group trialsProportional hazards regression modelsYoung adultsAdjusted hazard ratioChildren's Oncology GroupLong-term complicationsLong-term outcomesLog-rank testHazards regression modelsPediatric clinical trialsCancer clinical trial participantsLow socioeconomic status areasLong-term survivalEthnic minority patientsQuality of lifeLow socioeconomic statusNon-Hispanic whites
2022
Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group
Dicken B, Billmire D, Rich B, Hazard F, Nuño M, Krailo M, Fallahazad N, Pashankar F, Shaikh F, Frazier A. Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group. Gynecologic Oncology 2022, 166: 476-480. PMID: 35750503, PMCID: PMC9514449, DOI: 10.1016/j.ygyno.2022.06.013.Peer-Reviewed Original ResearchConceptsIntra-operative frozen sectionOvarian germ cell tumorsGerm cell tumorsMalignant ovarian germ cell tumorsIntra-operative frozen section diagnosisFrozen section diagnosisCentral pathology reviewCell tumorsSurgical stagingAdolescent patientsFinal diagnosisFinal paraffin section diagnosisSection diagnosisFrozen sectionsParaffin section diagnosisOncology GroupPathology reviewCentral reviewOvarian germ cell malignanciesNonseminomatous germ cell tumorsGerm cell tumor componentsConfirmation of malignancyGerm cell malignanciesRecords of patientsChildren's Oncology Group
2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group
Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 890-900. PMID: 34767937, PMCID: PMC9038118, DOI: 10.1016/j.ijrobp.2021.10.152.Peer-Reviewed Original ResearchConceptsInvolved-field radiation therapySlow early responseClassical Hodgkin lymphomaBulky diseaseOncology GroupHodgkin's lymphomaRetrospective analysisChildren's Oncology Group protocolsHigh-risk Hodgkin lymphomaRadiation treatment volumesCycles of doxorubicinHigh-risk patientsPhase 3 studyTime of progressionChildren's Oncology GroupPatterns of failureInitial siteABVE-PCConsolidation RTEligible patientsField relapseInitial relapseMedian followRelapse siteStage IIIBThe Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity
Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Herrera A, Friedberg J, Friedman D, Schwartz C, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity. Blood 2021, 138: 881. DOI: 10.1182/blood-2021-147678.Peer-Reviewed Original ResearchInvolved site radiotherapyCardiac radiation doseInvolved-field radiotherapyChildhood Cancer Survivor StudyPositron emission tomographyMediastinal radiotherapyChildren's Oncology GroupDoxorubicin doseCumulative incidenceCardiac toxicityCardiac diseaseRT useCardiac riskCardiac disease riskBulk diseaseOncology GroupLymphoma trialsTrial protocolRadiation doseLong-term cardiac riskDisease riskCumulative doxorubicin doseImpact of nivolumabLate cardiac toxicityMean heart doseTreatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol
Rodriguez-Galindo C, Krailo MD, Pinto EM, Pashankar F, Weldon CB, Huang L, Caran EM, Hicks J, McCarville MB, Malkin D, Wasserman JD, de Oliveira Filho AG, LaQuaglia MP, Ward DA, Zambetti G, Mastellaro MJ, Pappo AS, Ribeiro RC. Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. Journal Of Clinical Oncology 2021, 39: 2463-2473. PMID: 33822640, PMCID: PMC8462560, DOI: 10.1200/jco.20.02871.Peer-Reviewed Original ResearchConceptsRetroperitoneal lymph node dissectionLymph node dissectionOutcomes of patientsAdrenocortical carcinomaNode dissectionStage IOncology GroupStage IV adrenocortical carcinomaStage-III adrenocortical carcinomaPediatric-specific studiesStage II diseaseEvent-free survivalStage II patientsThird of patientsOverall survival estimatesChildren's Oncology GroupHigh-risk groupCombination of mitotaneAggressive pediatric malignancyPediatric adrenocortical carcinomaAdvanced diseaseII patientsMultivariable analysisPoor outcomeExcellent outcomesPediatric classical Hodgkin lymphoma
Lo AC, Dieckmann K, Pelz T, Gallop‐Evans E, Engenhart‐Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, Hodgson D. Pediatric classical Hodgkin lymphoma. Pediatric Blood & Cancer 2021, 68: e28562. PMID: 33818890, DOI: 10.1002/pbc.28562.Peer-Reviewed Original ResearchConceptsClassical Hodgkin lymphomaChildren's Oncology GroupPediatric classical Hodgkin lymphomaHodgkin's lymphomaRadiation therapyOncology GroupUtilization of RTHigh-risk patientsBulk of diseaseHigh cure ratesUniformly fatal diseaseLong-term toxicityIntensity of treatmentEuroNet-PHLB symptomsRisk patientsCurable cancerLymphoma trialsRT volumeCure rateTumor stageImmunoregulatory drugsTrial groupChemotherapy agentsHL management
2020
Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology
Billmire D, Dicken B, Rescorla F, Ross J, Piao J, Huang L, Krailo M, Pashankar F, Frazier L, Group C. Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology. Journal Of Pediatric And Adolescent Gynecology 2020, 34: 383-386. PMID: 33316416, PMCID: PMC8096645, DOI: 10.1016/j.jpag.2020.11.014.Peer-Reviewed Original ResearchConceptsMalignant ovarian germ cell tumorsMalignant germ cell tumorsGerm cell tumorsOvarian germ cell tumorsCell tumorsOncology GroupMalignant histologyImaging appearancesExtracranial malignant germ cell tumorsNonseminomatous malignant germ cell tumorsOvarian malignant germ cell tumorsSolid appearanceComplete surgical stagingElement of teratomaPediatric ovarian neoplasmsPreoperative serum markersChildren's Oncology GroupPrimary ovarian tumorsYolk sac tumorYears of ageAssociated teratomaTeratoma elementsSurgical stagingMixed histologyMulticenter trialPatterns of Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group
Parikh R, Hoppe B, Hodgson D, McCarten K, Pei Q, Cho S, Schwartz C, Cole P, Kelly K, Roberts K. Patterns of Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: s36-s37. DOI: 10.1016/j.ijrobp.2020.07.2140.Peer-Reviewed Original ResearchPractice patterns and recommendations for pediatric image‐guided radiotherapy: A Children's Oncology Group report
Hua C, Vern‐Gross T, Hess CB, Olch AJ, Alaei P, Sathiaseelan V, Deng J, Ulin K, Laurie F, Gopalakrishnan M, Esiashvili N, Wolden SL, Krasin MJ, Merchant TE, Donaldson SS, FitzGerald TJ, Constine LS, Hodgson DC, Haas‐Kogan D, Mahajan A, Laack NN, Marcus KJ, Taylor PA, Ahern VA, Followill DS, Buchsbaum JC, Breneman JC, Kalapurakal JA. Practice patterns and recommendations for pediatric image‐guided radiotherapy: A Children's Oncology Group report. Pediatric Blood & Cancer 2020, 67: e28629. PMID: 32776500, PMCID: PMC7774502, DOI: 10.1002/pbc.28629.Peer-Reviewed Original ResearchConceptsChildren's Oncology GroupImage-guided radiotherapyOncology GroupPractice patternsOncology disciplinesChildren's Oncology Group reportPaediatric radiotherapy patientsTreatment modalitiesExpert guidelinesDose reductionRadiotherapy patientsPractice recommendationsSetup correctionAdaptive therapyRadiotherapyImage guidanceReportMember surveyGroup ReportPatientsTherapyClinicians
2019
α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium
O’Neill A, Xia C, Krailo MD, Shaikh F, Pashankar FD, Billmire DF, Olson TA, Amatruda JF, Villaluna D, Huang L, Malogolowkin M, Rodriguez‐Galindo C, Frazier AL. α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer 2019, 125: 3649-3656. PMID: 31355926, DOI: 10.1002/cncr.32363.Peer-Reviewed Original ResearchConceptsGerm cell tumorsChildren's Oncology GroupCell tumorsAFP declineCumulative incidenceOncology GroupOverall survivalPediatric patientsThree-year overall survivalFuture clinical trial designTumor marker declineStart of chemotherapyPredictors of outcomeRecognition of patientsClinical trial designYears of ageAdult patientsPoor prognosisSerum AFPMarker declineStratified analysisHigh riskTrial designPatientsEarly intensificationResponse‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. British Journal Of Haematology 2019, 187: 39-48. PMID: 31180135, PMCID: PMC6857800, DOI: 10.1111/bjh.16014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCyclophosphamideDoxorubicinDrug Administration ScheduleDrug MonitoringEtoposideFemaleHodgkin DiseaseHumansIfosfamideMaleNeoplasm StagingPositron-Emission TomographyPrednisoneProspective StudiesRadiotherapy, AdjuvantRecurrenceTreatment OutcomeVincristineVinorelbineYoung AdultConceptsHigh-risk Hodgkin lymphomaABVE-PCOncology GroupHodgkin's lymphomaEarly respondersRapid early respondersEnd of chemotherapyEvent-free survivalOverall survival rateResponse-adapted therapyChildren's Oncology GroupTreatment of childrenPET-positive lesionsAlkylator exposureOS ratesActive diseaseTreat analysisPediatric patientsRadiotherapy volumeClinical evidenceEarly progressionRadiation volumeRecent trialsPositive lesionsSER patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply